Skip to main content
Top
Published in: Annals of Surgical Oncology 13/2022

18-08-2022 | Metastasis | Melanoma

Tumor Growth Rate as a Predictive Marker for Recurrence and Survival After Liver Resection in Patients with Liver Metastases of Uveal Melanoma

Authors: Toulsie Ramtohul, MD, Mohamed Abdul-Baki, MD, Manuel Rodrigues, MD, PhD, Nathalie Cassoux, MD, PhD, Sophie Gardrat, MD, Khadija Ait Rais, MD, Gaëlle Pierron, MD, PhD, Toufik Bouhadiba, MD, Vincent Servois, MD, Pascale Mariani, MD

Published in: Annals of Surgical Oncology | Issue 13/2022

Login to get access

Abstract

Background

Surgical management of liver metastases of uveal melanoma (LMUM) is associated with the best survival rates, especially for patients with a low tumor burden in the liver. The aim was to determine whether the tumor growth rate (TGR0) before liver resection helps predict survival in patients with resectable LMUM.

Methods

This retrospective study included 99 patients with LMUM treated with liver resection between November 2007 and November 2020. TGR0 was expressed as the percentage change in tumor volume over 1 month according to two pretreatment imaging scans. Multivariate Cox analyses identified independent predictors of disease-free survival (DFS) and overall survival (OS).

Results

DFS and OS had a statistically significant positive linear relationship (Spearman correlation r = 0.68, p < 0.001). A disease-free interval (DFI) > 24 months and a TGR0 ≤ 50%/month were independent factors associated with better DFS and OS. The 2-component model including TGR0 and DFI had a mean time-dependent area under the curve (AUC) of 0.81 (95% CI, 0.75–0.86) and 0.77 (95% CI, 0.67–0.87), respectively, for predicting DFS and OS. DFI with TGR0 defined three kinetic risk groups that had distinct DFS and OS outcomes (p < 0.001). Cytogenetic alterations at baseline were partially predictive factors of the kinetic risk score based on TGR0 and DFI.

Discussion

The assessment of TGR0 improves prognostic stratification by identifying patients at high risk of recurrence and poor survival after liver resection. TGR0 and DFI, reflecting tumor aggressivity, have the potential to be important markers for systemic adjuvant decisions.
Appendix
Available only for authorised users
Literature
1.
go back to reference Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881–5.CrossRefPubMed Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881–5.CrossRefPubMed
2.
go back to reference Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29:561–8.CrossRefPubMedPubMedCentral Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29:561–8.CrossRefPubMedPubMedCentral
3.
go back to reference Carvajal RD, Schwartz GK, Tezel T, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101:38–44.CrossRefPubMed Carvajal RD, Schwartz GK, Tezel T, et al. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101:38–44.CrossRefPubMed
4.
go back to reference Mouriaux F, Servois V, Parienti JJ, et al. Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study. Br J Cancer. 2016;115:20–4.CrossRefPubMedPubMedCentral Mouriaux F, Servois V, Parienti JJ, et al. Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study. Br J Cancer. 2016;115:20–4.CrossRefPubMedPubMedCentral
5.
go back to reference Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018;36:1232–9.CrossRefPubMed Carvajal RD, Piperno-Neumann S, Kapiteijn E, et al. Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter, randomized trial (SUMIT). J Clin Oncol. 2018;36:1232–9.CrossRefPubMed
6.
go back to reference Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39:599–607.CrossRefPubMed Pelster MS, Gruschkus SK, Bassett R, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39:599–607.CrossRefPubMed
7.
go back to reference Piulats JM, Espinosa E, de la Cruz Merino L, et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402). J Clin Oncol. 2021;39:586–98.CrossRefPubMed Piulats JM, Espinosa E, de la Cruz Merino L, et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402). J Clin Oncol. 2021;39:586–98.CrossRefPubMed
8.
go back to reference Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol. 2010;74:e38-44.CrossRefPubMed Huppert PE, Fierlbeck G, Pereira P, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol. 2010;74:e38-44.CrossRefPubMed
9.
go back to reference Gonsalves CF, Eschelman DJ, Adamo RD, et al. A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology. 2019;293:223–31.CrossRefPubMed Gonsalves CF, Eschelman DJ, Adamo RD, et al. A prospective phase II trial of radioembolization for treatment of uveal melanoma hepatic metastasis. Radiology. 2019;293:223–31.CrossRefPubMed
10.
go back to reference Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385:1196–206.CrossRefPubMed Nathan P, Hassel JC, Rutkowski P, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N Engl J Med. 2021;385:1196–206.CrossRefPubMed
11.
go back to reference Gomez D, Wetherill C, Cheong J, et al. The Liverpool uveal melanoma liver metastases pathway: outcome following liver resection. J Surg Oncol. 2014;109:542–7.CrossRefPubMed Gomez D, Wetherill C, Cheong J, et al. The Liverpool uveal melanoma liver metastases pathway: outcome following liver resection. J Surg Oncol. 2014;109:542–7.CrossRefPubMed
12.
go back to reference Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol. 2009;35:1192–7.CrossRefPubMed Mariani P, Piperno-Neumann S, Servois V, et al. Surgical management of liver metastases from uveal melanoma: 16 years’ experience at the Institut Curie. Eur J Surg Oncol. 2009;35:1192–7.CrossRefPubMed
13.
go back to reference Lamarca A, Ronot M, Moalla S, et al. Tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumors: the GREPONET-2 study. Clin Cancer Res. 2019;25:6692–9.CrossRefPubMed Lamarca A, Ronot M, Moalla S, et al. Tumor growth rate as a validated early radiological biomarker able to reflect treatment-induced changes in neuroendocrine tumors: the GREPONET-2 study. Clin Cancer Res. 2019;25:6692–9.CrossRefPubMed
15.
go back to reference Ramtohul T, Ait Rais K, Gardrat S, et al. Prognostic implications of MRI melanin quantification and cytogenetic abnormalities in liver metastases of uveal melanoma. Cancers. 2021;13:2728.CrossRefPubMedPubMedCentral Ramtohul T, Ait Rais K, Gardrat S, et al. Prognostic implications of MRI melanin quantification and cytogenetic abnormalities in liver metastases of uveal melanoma. Cancers. 2021;13:2728.CrossRefPubMedPubMedCentral
16.
go back to reference for the statistics subcommittee of the NCI—EORTC working group on cancer diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Rev Clin Oncol. 2005;2:416–422. for the statistics subcommittee of the NCI—EORTC working group on cancer diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Rev Clin Oncol. 2005;2:416–422.
17.
go back to reference Ferté C, Koscielny S, Albiges L, et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. Eur Urol. 2014;65:713–20.CrossRefPubMed Ferté C, Koscielny S, Albiges L, et al. Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data. Eur Urol. 2014;65:713–20.CrossRefPubMed
18.
go back to reference Rivoire M, Kodjikian L, Baldo S, et al. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol. 2005;12:422–8.CrossRefPubMed Rivoire M, Kodjikian L, Baldo S, et al. Treatment of liver metastases from uveal melanoma. Ann Surg Oncol. 2005;12:422–8.CrossRefPubMed
19.
go back to reference Nakamura T, Matsumine A, Matsubara T, et al. Clinical impact of the tumor volume doubling time on sarcoma patients with lung metastases. Clin Exp Metastasis. 2011;28:819–25.CrossRefPubMed Nakamura T, Matsumine A, Matsubara T, et al. Clinical impact of the tumor volume doubling time on sarcoma patients with lung metastases. Clin Exp Metastasis. 2011;28:819–25.CrossRefPubMed
20.
go back to reference Arai T, Kuroishi T, Saito Y, et al. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol. 1994;24:199–204.PubMed Arai T, Kuroishi T, Saito Y, et al. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol. 1994;24:199–204.PubMed
21.
go back to reference Nathani P, Gopal P, Rich N, et al. Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut. 2021;70:401.PubMed Nathani P, Gopal P, Rich N, et al. Hepatocellular carcinoma tumour volume doubling time: a systematic review and meta-analysis. Gut. 2021;70:401.PubMed
22.
go back to reference Miyake H, Murono K, Nagata H, et al. Prognostic significance of doubling time in patients undergoing radical surgery for metachronous peritoneal metastases of colorectal cancer. Int J Colorectal Dis. 2019;34:801–9.CrossRefPubMed Miyake H, Murono K, Nagata H, et al. Prognostic significance of doubling time in patients undergoing radical surgery for metachronous peritoneal metastases of colorectal cancer. Int J Colorectal Dis. 2019;34:801–9.CrossRefPubMed
23.
go back to reference Eskelin S, Pyrhonen S, Summanen P, et al. Tumor doubling times in metastatic malignant melanoma of the uvea. Evid-Based Ophthalmol. 2000;107:7. Eskelin S, Pyrhonen S, Summanen P, et al. Tumor doubling times in metastatic malignant melanoma of the uvea. Evid-Based Ophthalmol. 2000;107:7.
24.
go back to reference Valpione S, Moser JC, Parrozzani R, et al. Development and external validation of a prognostic nomogram for metastatic uveal melanoma. PLoS ONE. 2015;12:e0120181.CrossRef Valpione S, Moser JC, Parrozzani R, et al. Development and external validation of a prognostic nomogram for metastatic uveal melanoma. PLoS ONE. 2015;12:e0120181.CrossRef
25.
go back to reference Mariani P, Dureau S, Savignoni A, et al. Development of a prognostic nomogram for liver metastasis of uveal melanoma patients selected by liver MRI. Cancers. 2019;11:863.CrossRefPubMedCentral Mariani P, Dureau S, Savignoni A, et al. Development of a prognostic nomogram for liver metastasis of uveal melanoma patients selected by liver MRI. Cancers. 2019;11:863.CrossRefPubMedCentral
26.
go back to reference Mariani P, Almubarak MM, Kollen M, et al. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur J Surg Oncol. 2016;42:706–12.CrossRefPubMed Mariani P, Almubarak MM, Kollen M, et al. Radiofrequency ablation and surgical resection of liver metastases from uveal melanoma. Eur J Surg Oncol. 2016;42:706–12.CrossRefPubMed
27.
go back to reference Robertson AG, Shih J, Yau C, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32:204-220.e15.CrossRefPubMedPubMedCentral Robertson AG, Shih J, Yau C, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell. 2017;32:204-220.e15.CrossRefPubMedPubMedCentral
28.
go back to reference Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538–43.CrossRefPubMed Tauriello DVF, Palomo-Ponce S, Stork D, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538–43.CrossRefPubMed
30.
go back to reference Kito A, Tanaka K, Fujimaki H, et al. Tumor doubling time and local immune response to hepatic metastases from colorectal cancer. J Surg Oncol. 2007;96:525–33.CrossRefPubMed Kito A, Tanaka K, Fujimaki H, et al. Tumor doubling time and local immune response to hepatic metastases from colorectal cancer. J Surg Oncol. 2007;96:525–33.CrossRefPubMed
Metadata
Title
Tumor Growth Rate as a Predictive Marker for Recurrence and Survival After Liver Resection in Patients with Liver Metastases of Uveal Melanoma
Authors
Toulsie Ramtohul, MD
Mohamed Abdul-Baki, MD
Manuel Rodrigues, MD, PhD
Nathalie Cassoux, MD, PhD
Sophie Gardrat, MD
Khadija Ait Rais, MD
Gaëlle Pierron, MD, PhD
Toufik Bouhadiba, MD
Vincent Servois, MD
Pascale Mariani, MD
Publication date
18-08-2022
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2022
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-022-12368-5

Other articles of this Issue 13/2022

Annals of Surgical Oncology 13/2022 Go to the issue